サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1280533

バイオソルバブルステントの世界市場

Bioresorbable Stents
出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 125 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
バイオソルバブルステントの世界市場
出版日: 2023年01月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 125 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

バイオソルバブルステントの世界市場は2030年に12億米ドルに達する

変化したCOVID-19後のビジネス環境において、2022年に4億9,670万米ドルと推定されるバイオソルバブルステントの世界市場は、2030年までに12億米ドルの改定規模に達し、分析期間2022-2030年に12%のCAGRで成長すると予測されます。本レポートで分析したセグメントの1つであるポリマーベースのバイオソルバブルステントは、CAGR12.8%を記録し、分析期間終了時には9億520万米ドルに達すると予測されます。パンデミック後の回復を考慮し、金属ベースのバイオソルバブルステント分野の成長は、今後8年間のCAGRが10.2%に修正される見込みです。

欧州市場は2億1,360万米ドル、アジア太平洋地域はCAGR10.8%で成長すると予測される

欧州のバイオソルバブルステント市場は、2022年に2億1,360万米ドルと推定されます。アジア太平洋地域の市場規模は、2022年から2030年にかけてCAGR 10.8%で推移し、2030年には4億8,220万米ドルに達すると予測されています。

調査対象企業の例

  • Abbott Laboratories, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Eurocor GmbH
  • Biosensors International Group Ltd.
  • Elixir Medical Corporation
  • InSitu Technologies, Inc.
  • Kyoto Medical Planning Co., Ltd.
  • Medinol Ltd.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Alvimedica Saglik Ekipmanlari Pazarlama Satis ve Dagitim A.S.
  • Meril Life Sciences Pvt., Ltd.
  • Arterial Remodeling Technologies SA
  • iVascular S.L.U
  • Endocor GmbH

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 世界市場概要
  • 市場の見通し
  • 競合
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP10697

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Bioresorbable Stents Market to Reach $1.2 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Bioresorbable Stents estimated at US$496.7 Million in the year 2022, is projected to reach a revised size of US$1.2 Billion by 2030, growing at a CAGR of 12% over the analysis period 2022-2030. Polymer-based Bioresorbable Stents, one of the segments analyzed in the report, is projected to record a 12.8% CAGR and reach US$905.2 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Metal-based Bioresorbable Stents segment is readjusted to a revised 10.2% CAGR for the next 8-year period.

The Europe Market is Estimated at $213.6 Million, While Asia-Pacific is Forecast to Grow at 10.8% CAGR

The Bioresorbable Stents market in Europe is estimated at US$213.6 Million in the year 2022. Asia-Pacific is forecast to reach a projected market size of US$482.2 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2022 to 2030.

Select Competitors (Total 25 Featured) -

  • Abbott Laboratories, Inc.
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Eurocor GmbH
  • Biosensors International Group Ltd.
  • Elixir Medical Corporation
  • InSitu Technologies, Inc.
  • Kyoto Medical Planning Co., Ltd.
  • Medinol Ltd.
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Alvimedica Saglik Ekipmanlari Pazarlama Satis ve Dagitim A.S.
  • Meril Life Sciences Pvt., Ltd.
  • Arterial Remodeling Technologies SA
  • iVascular S.L.U
  • Endocor GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Bioresorbable Stents - Global Key Competitors Percentage Market Share in 2022 (E)
    • Coronary Artery Disease (CAD) - A Perspective
    • Causes and Symptoms
    • Treatment Options for Coronary Artery Disease
    • Percutaneous Coronary Intervention (PCI)
    • Coronary Stenting
    • Types of Coronary Stents
    • Bare Metal Stents (BMS)
    • Drug Eluting Stents (DES)
    • Bioresorbable Scaffolds
    • Design and Composition of Bioresorbable Scaffolds
    • Different Types of Bioresorbable Scaffolds
    • Metallic Bioresorbable Scaffolds
    • Polymer Bioresorbable Scaffolds
    • Degradation Period of Select Bioabsorbable Materials
    • Challenges
    • Clinical Characteristics of Various Coronary Stents
    • Other Treatment Options for Coronary Heart Disease
    • Coronary Artery Bypass Grafting (CABG)
    • Minimally Invasive Direct Coronary Artery Bypass (MIDCAB)
    • TransMyocardial Laser Revascularization (TMR)
    • Peripheral Arterial Disease: Understanding the Stealthy Peril
    • Treatment for PAD
    • Stenting- A Treatment Option for PAD
    • BioResorbable Stents - A Prelude
    • Bioresorbable Vascular Scaffolds: Advantages and Challenges
    • Bioresorbable Stents - A Revolutionary Technology, Riddled with Controversies
    • Abbott Stops Sales of the Once Promising 'Absorb' Bioresorbable Stents due to Adverse Events
    • Impact of Abbott's Withdrawal of Absorb on the Bioresorbable Stent Industry
    • Impact of Covid-19 and a Looming Global Recession
    • 2020 Marked as a Year of Disruption & Transformation
    • World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    • Impact of COVID - 19 on Coronary Stents Market
    • Impact on Supply Chain
    • Impact of COVID-19 Outbreak on Elective Surgeries
    • Global Bioresorbable Stents Market Buckles under COVID-19 Strain
  • GLOBAL MARKET OVERVIEW
    • Global Bioresorbable Stents Set to Witness Growth in Future
    • Europe Dominates, Asia-Pacific Exhibits Fastest Growth
    • CAD Constitutes the Leading Application
    • Metallic Vs. Polymer-based Stents
    • Bioabsorbable Metallic Stents
    • Bioabsorbable Polymer Stents
    • Disappointing Results by Absorb to Increase Focus on Metallic Stents
    • Availability of Alternative Treatments - Hindrance to Market Growth
    • Market Challenges
  • MARKET OUTLOOK
    • Bioresorbable and Integrated Biosensor Technology to Redefine Future of Vascular Stents
    • The Future of BRS Technology
  • COMPETITION
    • Select Approved Bioresorbable Scaffolds
    • Select Bioresorbable Stents in Pipeline
    • Abbott Revives Bioresorbable Stent Clinical Trials to Evaluate New Esprit Scaffold
    • Recent Market Activity
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Polymeric Resorbable Scaffolds Hold a Major Market Share
    • The Absorb BRS program
    • Desaminotyrosine Polycarbonate-based BRS
    • The FANTOM program
    • Magnesium-based BRS
    • The Magmaris program
    • Iron-based BRS
    • Global Menace of Coronary Artery Disease (CAD) - A Major Growth Driver
    • Global Annual Medical Cost of CVD in the United States: 2015-2030
    • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Ageing Demographics and Longer Life Expectancy Bolsters Market Growth
    • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Rising Middle Class Population Aids Growth
    • Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P
    • Rising Healthcare Expenditure: Opportunities in Store
    • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
    • Risk of CAD in Obesity Offers Prospects for Coronary Stenting
    • Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Diabetics at Higher Risk of Heart Diseases
    • TABLE 15: Diabetes Prevalence Worldwide by Region: Number of Adults (20-79 Years) with Diabetes in 2015 and 2040
    • The Hypertension-Cholesterol Link to Drive Demand
    • Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years
    • Metal Bioresorbable scaffolds Exhibit Improved Performance Compared to Polymer Stents
    • Metal Stents Vis-a-Vis Other Stents
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Bioresorbable Stents by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World 8-Year Perspective for Bioresorbable Stents by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Polymer-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 4: World 8-Year Perspective for Polymer-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Metal-based by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 6: World 8-Year Perspective for Metal-based by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Coronary Artery Disease/CAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World 8-Year Perspective for Coronary Artery Disease/CAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Peripheral Artery Disease/PAD by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 10: World 8-Year Perspective for Peripheral Artery Disease/PAD by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 12: World 8-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Cardiovascular Centers by Geographic Region - Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World 8-Year Perspective for Cardiovascular Centers by Geographic Region - Percentage Breakdown of Value Sales for Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
    • TABLE 15: World Bioresorbable Stents Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030

III. MARKET ANALYSIS

  • EUROPE
    • Bioresorbable Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 16: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 17: Europe 8-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2023 & 2030
    • TABLE 18: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 19: Europe 8-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2023 & 2030
    • TABLE 20: Europe Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 21: Europe 8-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2023 & 2030
  • ASIA-PACIFIC
    • Bioresorbable Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 22: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 23: Asia-Pacific 8-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2023 & 2030
    • TABLE 24: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 25: Asia-Pacific 8-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2023 & 2030
    • TABLE 26: Asia-Pacific Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Asia-Pacific 8-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2023 & 2030
  • REST OF WORLD
    • TABLE 28: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Material - Polymer-based and Metal-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 29: Rest of World 8-Year Perspective for Bioresorbable Stents by Material - Percentage Breakdown of Value Sales for Polymer-based and Metal-based for the Years 2023 & 2030
    • TABLE 30: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by Application - Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 31: Rest of World 8-Year Perspective for Bioresorbable Stents by Application - Percentage Breakdown of Value Sales for Coronary Artery Disease/CAD and Peripheral Artery Disease/PAD for the Years 2023 & 2030
    • TABLE 32: Rest of World Recent Past, Current & Future Analysis for Bioresorbable Stents by End-Use - Hospitals and Cardiovascular Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Rest of World 8-Year Perspective for Bioresorbable Stents by End-Use - Percentage Breakdown of Value Sales for Hospitals and Cardiovascular Centers for the Years 2023 & 2030

IV. COMPETITION